NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Forecast & News

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has decreased by 18.0% and is now trading at $3.19. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals.

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Paratek Pharmaceuticals.

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its quarterly earnings results on Tuesday, February, 25th. The specialty pharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.03) by $0.22. The specialty pharmaceutical company had revenue of $8.97 million for the quarter, compared to analysts' expectations of $4.78 million. Paratek Pharmaceuticals had a negative return on equity of 5,327.73% and a negative net margin of 778.47%. View Paratek Pharmaceuticals' earnings history.

Paratek Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $68.08 million.

7 Wall Street analysts have issued 12 month price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they expect Paratek Pharmaceuticals' stock price to reach $17.20 in the next year. This suggests a possible upside of 439.2% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals.

Media coverage about PRTK stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutParatek Pharmaceuticals.

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), EXACT Sciences (EXAS), Exelixis (EXEL), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Amarin (AMRN).

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.04%), General American Investors Co. Inc. (1.94%), ICM Asset Management Inc. WA (1.35%), Water Island Capital LLC (1.26%), Goldman Sachs Group Inc. (1.03%) and Roumell Asset Management LLC (1.02%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View institutional ownership trends for Paratek Pharmaceuticals.

PRTK stock was sold by a variety of institutional investors in the last quarter, including Roumell Asset Management LLC, General American Investors Co. Inc., J. Goldman & Co LP, Trellus Management Company LLC, Water Island Capital LLC, Nuveen Asset Management LLC, and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Randall B Brenner, and William M Haskel. View insider buying and selling activity for Paratek Pharmaceuticals.

PRTK stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Goldman Sachs Group Inc., ICM Asset Management Inc. WA, Smith Asset Management Group LP, Banco Bilbao Vizcaya Argentaria S.A., Stifel Financial Corp, Oxford Asset Management LLP, and Marshall Wace LLP. View insider buying and selling activity for Paratek Pharmaceuticals.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRTK stock can currently be purchased for approximately $3.19.

Paratek Pharmaceuticals has a market capitalization of $134.68 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe. View additional information about Paratek Pharmaceuticals.

The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]